Quotient Therapeutics的动态

High lipoprotein(a) [Lp(a)] is a significant, genetically determined risk factor for cardiovascular disease that should be measured at least once in a lifetime. One in five people are at increased risk for conditions like atherosclerosis and aortic valve stenosis due to high Lp(a) levels, which vary across populations and are 17% higher in post-menopausal women. Although no approved drugs currently exist to lower Lp(a), five promising treatments in clinical trials show potential for reducing levels by up to 98%. Awareness, early screening, and future therapies could be key to reducing cardiovascular risk. https://lnkd.in/gEa6R5tA #CardiovascularHealth #LipoproteinA #HeartDisease #Genetics #HeartHealth #Atherosclerosis #ClinicalTrials #HeartRisk #HealthScreening #PreventiveMedicine #PublicHealth #HealthyLiving #GeneticRisk #MedicalResearch #WomenInHealth #Cardiology #FutureOfMedicine #HealthAwareness #PersonalizedCare #CardiovascularResearch

World Liver Day is celebrated every year on 19 April to raise awareness and spread knowledge of chronic liver diseases, including Acute-on-Chronic Liver Failure (ACLF)?a rapid-onset disease that currently has no approved treatments and is associated with a high mortality rate, up to 75% at 3 months. Our HepaStem? therapy, which is currently in clinical development stage, has the potential to allow recovery and regeneration of the body’s own liver cells and offers hope for the 100,000 patients who suffer from ACLF worldwide. Data from our recently completed phase II clinical trials is expected in H2 2024. ?? Read the EASL | The Home of Hepatology fact sheet on ACLF: https://ibb.co/sbsG528 ?? World Liver Day: https://lnkd.in/eKxD3-uF ??Learn how we are redefining liver treatments through cell therapies: www.cellaion.com #WorldLiverDay #StepUpForLiverHealth #Biotech #LiverFailure #UnmetMedicalNeed #ACLF

Probing advancements in lipid nanoparticle-mediated mRNA delivery for cardiovascular diseases: in this comprehensive review article, Setareh Soroudi, Mahmoud Reza Jaafari and Leila Arabi at Mashhad University of Medical Sciences highlighted recent progress in mRNA-LNP therapies for cardiovascular diseases, including myocardial infarction, heart failure, hypercholesterolemia, CAR T-cell therapy, CRISPR/Cas genome editing, and related clinical trials https://lnkd.in/eEGcSkrj They determined that strategies to enhance extra-hepatic delivery and targeted organ tropism of mRNA-LNPs hold significant promise for advancing the development and translation of mRNA-LNP therapies for cardiovascular disease treatment. #LNPs #CRISPR #mRNA #cardiovasculardiseases #drugdelivery #Vesiculab

?? Non-Alcoholic Fatty Liver Disease (NAFLD) and its Progression: The Role of Micro-RNAs as Biomarkers ?? Understanding the spectrum of Non-Alcoholic Fatty Liver Disease (NAFLD) is crucial in early diagnosis and effective management. From a healthy liver to NAFL, NASH, cirrhosis, and eventually hepatocellular carcinoma, the progression is complex and multifaceted. Micro-RNAs have emerged as powerful biomarkers for tracking these changes, offering insights into disease development and potential therapeutic targets. Explore how these molecular indicators can enhance our approach to liver health. #LiverHealth #NAFLD #MicroRNA #BiomedicalResearch #HealthDiagnostics #PrimaNexus

NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s Disease phase Ib/IIa trial. The positive data from its Phase Ib/IIa study indicates that NT-0796 reduces key neuroinflammatory and inflammatory biomarkers in Parkinson’s disease patients to the levels found in healthy elderly controls over 28 days. The NLRP3 inflammasome is a main mediator of inflammation in many pathologies. NT-0796 selectively inhibits NLRP3, lowering levels of both pro-inflammatory cytokines IL-1β and IL-18. This action delivers therapeutic effects directly to immune cell types responsible for inflammatory diseases, including peripheral and neuroinflammatory diseases. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/ggT24Qr9 ? #Parkinson #Disease #clinical #Buildingblocks #NLRP3 #inflammasome #Inhibitor #brain #cytokine

Happy to share my research !!! In this work, we used metabolomics to identify alkyl-LPCs as secondary storage metabolite in NPC1 disease. Our findings unveiled a substantial elevation in the levels of three alkyl-lysophosphatidylcholine (alkyl-LPC, also known as lyso-platelet activating factor (lyso-PAF) species in NPC1 compared to controls across various tissues, including brain tissue from individuals with NPC1, liver, spleen, cerebrum, cerebellum, and brain stem from NPC1 mice, as well as in both brain and liver tissue from NPC1 cats.?Alkyl-LPC species may serve as potential markers for NPC1 pathogenesis, a target for therapeutic intervention, and for treatment response monitoring.?

Exploring Mitochondrial Dynamics in Parkinson’s Disease: Insights for Future Therapeutics ???? Parkinson’s Disease (PD), a complex neurodegenerative disorder, is characterized by the progressive loss of dopaminergic neurons and the presence of Lewy bodies, rich in α-synuclein. The role of mitochondrial dysfunction in PD's pathogenesis is a focal point of current research ??. This dysfunction is intricately linked to genetic factors, with evidence suggesting that PD-related genes affect mitochondrial integrity. However, there's a gap between theoretical knowledge and practical outcomes. Despite the development of numerous PD drugs targeting mitochondria, their clinical efficacy has been less than ideal ??. This highlights the need for a more nuanced understanding of mitochondrial dysfunction in neurodegenerative diseases. In this latest review, authors delve deep into the mitochondrial structure and function, aiming to unravel how these elements contribute to the pathogenesis of PD. The review is a step towards identifying potential interventions and therapeutic targets for PD, focusing on rectifying mitochondrial dysfunction in neurodegenerative diseases ??. link: https://lnkd.in/gW5SmUbp #ParkinsonsDisease #MitochondrialDysfunction #Neurodegeneration #ClinicalResearch #PharmaceuticalInnovation

112 million. 112 million people worldwide suffer from liver cirrhosis. Shocking as that may be, liver cirrhosis is commonly misunderstood, as it is not just alcohol related, nor does its effects remain limited to the liver. I am excited to share my latest research together with Annelotte Broekhoven, Minneke Coenraad, and Vincent van Duinen, in which we explore the utilization of endothelial cells to stratify liver cirrhosis patients. The ex vivo, high-content screening technology presented allows to quantify the ex vivo responses of the endothelium to patient plasma, opening the door to study the involvement of the endothelium not just in liver cirrhosis, but many other systemic diseases as well. https://lnkd.in/esmNirDd

“Somatic?expansion” is a hot topic in Huntington’s disease research.?Somatic?expansion is a process in which CAG repeats lengthen in some cells during aging. It’s thought to control how early HD symptoms appear. A group of researchers from Toronto, Canada recently identified proteins that may play an important role in regulating this process. Understanding how these proteins regulate?somatic?expansion in Huntington’s disease may hold the key for unlocking?therapeutics?for?CAG repeat?diseases. To read full article click here https://en.hdbuzz.net/353

?? Exciting new research alert! A recent study delves into potential biomarkers for overt hepatic encephalopathy (oHE) in cirrhosis patients. The investigation focuses on neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as plasma biomarkers. Results suggest that NfL could serve as a diagnostic marker for oHE, showing higher concentrations in ICU patients with oHE compared to controls. Interestingly, NfL concentrations correlated with Model for End-Stage Liver Disease (MELD) scores, indicating its potential as a severity marker. Read more about this groundbreaking research ?? https://lnkd.in/g3k5DHpm #Hepatology #Research #LiverDisease #Biomarkers.